The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
August 11th 2022, 11:16pm
The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.
August 11th 2022, 9:17pm
The case of warm autoimmune hemolytic anemia (AIHA) highlights the potential for life-threatening acute hemolysis if patients do not receive timely treatment.
August 11th 2022, 2:02pm
Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.
August 10th 2022, 9:15pm
The single-center study evaluated patients across multiple cancers to understand the utilization, safety, and financial outcomes of bevacizumab-awwb vs reference bevavizumab.
August 10th 2022, 8:56pm
The usefulness of sentinel lymph node (SLN) biopsy was investigated among patients with melanoma and SLN metastases.
August 10th 2022, 3:35pm
Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
August 9th 2022, 10:07pm
With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.
August 9th 2022, 1:00pm
This study presents an integrated, exploratory assessment of physical activity, patient activation, health-related quality of life, and clinical outcomes among older adults with type 2 diabetes (T2D) using survey, wellness, and claims data.
August 8th 2022, 9:40pm
Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.
August 8th 2022, 8:56pm
An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.